Cetuximab and Lenalidomide in Head and Neck: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Cetuximab and Lenalidomide in Head and Neck (NCT01133665), a na phase 2 study. The primary outcome is Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN..

2. Clinical Question

The study asks whether the presence of specific FcRIIIa polymorphisms is associated with progression-free survival among people with recurrent or metastatic squamous cell carcinoma of the head and neck who receive cetuximab and lenalidomide. The registry describes the purpose as examining the correlation between these polymorphisms and clinical outcome during treatment with the combination. It does not report which polymorphisms were assessed, their distribution, or a numerical estimate of the relationship with progression-free survival.

Because there is no control group, the study's central question is an association question within the treated group, not a randomized comparison of treatment strategies. The record does not establish whether any association was prespecified for particular genetic subgroups or how the analysis handled other prognostic factors.

3. Trial Design

This is a completed phase II study sponsored by the University of Chicago. The registry lists a single-group model, allocation as NA, and no masking. Enrollment is recorded as 42. The study start is listed as 2010-02 and primary completion as 2011-08. Its official title describes a study of cetuximab and lenalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.

All enrolled participants are described as belonging to the same subgroup, and the listed intervention is the combination of cetuximab and lenalidomide. There is no separate treatment arm to serve as a concurrent control. Consequently, the design does not support a like-for-like estimate of the combination's effect relative to another regimen or to no treatment. The record also does not describe random assignment, and its allocation field is NA.

The stated purpose focuses on FcRIIIa polymorphisms and clinical outcome during treatment. The primary outcome is progression-free survival, defined from the first treatment dose to the earlier of disease progression or death from any cause. The record specifies a 24 months timeframe and refers to RECIST v1.0 criteria for defining progression. It does not provide a numerical primary endpoint result, participant-level follow-up, or the number included in the primary analysis.

The registry lists 38 outcome measures and no analyses. Secondary outcomes include counts of participants with several named adverse events, including fatigue, rash, constipation, anemia, anorexia, nausea, hypoalbuminemia, and lymphopenia. The design description does not report details such as treatment schedule, eligibility criteria beyond the disease context, or planned statistical methods. Those details are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN., measured over 24 months.

The primary endpoint is progression-free survival, or PFS. It measures the time from the first administered treatment dose until the earlier of disease progression or death from any cause. In this study, progression is defined using RECIST v1.0: an increase of 20% in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions.

Time-to-event endpoints are used when the timing of an event matters and participants may have different lengths of observation. A participant who has not had progression or died by the last known assessment may contribute information up to that point without being treated as though the event occurred. This is generally called censoring. The registry record does not report the censoring rules used in analysis, how follow-up ended for participants, or how many participants experienced an event.

The stated scientific question concerns whether specific FcRIIIa polymorphisms correlate with PFS in people receiving the combination. A median can describe the time by which half of the relevant population has experienced the event, subject to the survival-analysis method and available follow-up. However, the registry record does not report a median PFS value, its full range, or a hazard ratio. It therefore defines what the endpoint is intended to measure, but does not provide a numerical estimate of PFS or of the association with polymorphism status.

The endpoint is clinically interpretable as a measure of time without documented progression or death, but it is not identical to overall survival: progression can occur before death and is determined by disease assessments. No inference about the observed course of participants can be made from the endpoint definition alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

For a time-to-event outcome, the central data are event times and the status of each participant at the end of observation. The event in this study is the earlier of disease progression or death from any cause. A participant whose event has not been observed by their last assessment is usually treated as censored at that time. In general, censoring allows information from incomplete follow-up to contribute without assuming that the event occurred. The registry defines the endpoint but does not report the censoring rules, event counts, or participant-level follow-up.

What a median time-to-event estimate means

In general, the median time-to-event estimate is the point at which the estimated proportion remaining event-free reaches one half. It is a summary of the survival curve, rather than an average of all observed times. Its interpretation depends on the event definition, follow-up, and analysis population. The registry lists median as the primary endpoint parameter and full range as the dispersion, but reports no median or range. A timeframe of 24 months is listed; this describes the recorded endpoint timeframe and does not establish that every participant was followed for that duration.

How a hazard ratio is used

In general, a hazard ratio compares event rates over time between groups or categories, under the assumptions of the model used. It is not a direct comparison of median times, and it does not describe an absolute difference in survival probability. A hazard ratio needs a specified contrast, and its interpretation also depends on the analysis model and assumptions. The record does not report a hazard ratio or identify a numerical polymorphism contrast. No hazard-ratio interpretation can therefore be made for this study. The statistical presentation uses only sponsor-reported hazard ratios when available; no such numerical result is reported in this record.

Confidence intervals and precision

In general, a confidence interval describes the uncertainty around an estimate under a statistical method. A narrower interval indicates greater precision under that method, while a wider interval indicates more uncertainty. It does not remove limitations in design or guarantee that an estimate is free of bias. Since the registry record gives no primary estimate or interval, its precision cannot be evaluated. A p-value, if reported, would address compatibility with a specified null model, not the size or importance of an association; no primary p-value is reported.

Association in a single-group study

In general, a single-group study can describe outcomes in the enrolled group and can examine associations between participant characteristics and outcomes. Such comparisons are not randomized treatment comparisons. Genetic or clinical subgroups may differ in other characteristics, and an unadjusted association may reflect those differences as well as the characteristic under study. Adjustment can address measured factors according to a prespecified model, but cannot automatically remove unmeasured confounding. The record does not report the model, covariates, subgroup definitions, or adjustment strategy used for the polymorphism question.

The study lists 42 participants enrolled, but the primary analysis population and the number with evaluable polymorphism and PFS data are not reported in the registry record. An enrollment count is not sufficient to determine how many participants contributed to a particular estimate. The safety record separately lists 40 participants at risk in each of its safety categories; this does not identify the PFS analysis population.

Over-dispersion and count outcomes

In general, over-dispersion occurs when count data vary more than a simple statistical model expects. It can make standard errors too small if the model does not account for the extra variation. This concept may matter for some event-count analyses, but the registry record does not report a count model or an analysis of such outcomes. The listed adverse-event outcomes are participant counts, and the record does not describe whether repeated events or event severity were modeled.

Planning calculations

The stated sample-size assumptions describe planning illustrations based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. For time-to-event illustrations, the stated quantity is the total number of events; other illustrations are expressed as participants per arm. These are planning calculations, not observed power. They do not establish the study's own design justification, and the equal-allocation, two-arm assumption is not a description of this trial's single-group design. The trial's own sample-size justification is not reported in the registry record.

The record lists no analyses. Consequently, descriptions of statistical methods must remain general rather than attributing a particular survival model, adjustment procedure, missing-data approach, or inferential framework to this study. Those methods are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 38 outcome measures, including the primary PFS question and secondary outcomes describing counts of participants with named adverse events. It lists no analyses. The record therefore does not specify which outcomes were included in statistical testing, how many hypotheses were tested, or whether analyses were planned for each listed outcome.

In general, testing many hypotheses can increase the chance of obtaining at least one apparently notable result by chance. Methods for addressing this issue include prespecifying a primary hypothesis, controlling an overall error rate, or treating secondary analyses as exploratory. The record does not report a multiplicity strategy, a hierarchy of outcomes, or whether any adjustment was applied. The list of outcomes alone does not show that all were formally tested.

The record does not describe missing-data handling, exclusions, censoring rules, or the analysis population for PFS. It also does not report the number of participants with available polymorphism data or the number contributing to the primary endpoint. These omissions limit the ability to judge whether the analysis population differed from enrollment, how incomplete assessments were treated, or how missing observations may have affected estimates.

In general, missing data can affect both precision and interpretation, especially when the reason data are unavailable is related to prognosis or treatment experience. The direction of any effect cannot be inferred without details about the amount and pattern of missingness and the analysis approach. Those details are not reported in the registry record. The listed enrollment and safety counts do not resolve these questions for the primary endpoint.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: death (7.5%), fever (7.5%), dehydration (5.0%), thromboembolic event (5.0%), febrile neutropenia (2.5%).

The safety record lists one intervention group, cetuximab and lenalidomide. It records 40 participants at risk for serious adverse events, with 16 affected, and 40 at risk for other adverse events, with 39 affected. These are participant counts in the registry's safety categories. They do not indicate the number of events per participant or provide a comparison with an untreated or alternative-treatment group.

The most frequently listed serious adverse event terms include Death and Fever, each at 7.5%; Dehydration and Thromboembolic event, each at 5.0%; and Febrile neutropenia and Acute coronary syndrome, each at 2.5%. These percentages are reported as event-term figures in the registry record. They should not be added together: the record does not say that the categories are mutually exclusive, and a participant may contribute to more than one category.

The term Death appears among the listed serious adverse event terms, but the record does not provide a separate death count in the group summary. Nor does it report event timing, severity grades, attribution details beyond the listed safety categorization, or a comparison group. The 42 enrolled participants should not be substituted for the 40 listed as at risk in the safety entries. These figures describe reported safety data and cannot establish comparative risk.

12. What the Result Does, and Does Not, Mean

The registry record shows that a phase II study of cetuximab and lenalidomide was completed, with a stated interest in the relationship between FcRIIIa polymorphisms and progression-free survival in recurrent or metastatic squamous cell carcinoma of the head and neck. It defines PFS and provides a timeframe, as well as a single-group design description. It also records selected adverse-event counts and terms.

What it does not show is the primary outcome estimate. There is no reported median PFS, full range, hazard ratio, confidence interval, or p-value for the polymorphism question. Without these results, the direction and magnitude of an association are unknown from the registry record. Statistical precision and the range of effects compatible with the data cannot be assessed.

The design also matters to interpretation. Because participants were not assigned to a separate control group, an association within the treated group would not establish that the treatment combination caused a difference in PFS. The record does not describe adjustment for other participant characteristics, so it cannot establish whether any association would be independent of other factors.

The safety figures describe reported events among participants at risk in the registry's safety categories. They do not provide comparative estimates, and the event terms may overlap. They should not be interpreted as a controlled comparison or as a complete description of the treatment experience.

In general, registry entries are useful for identifying study aims, design features, endpoint definitions, and posted results. A defined outcome is not itself an outcome finding. For this study, the record supports a careful account of what was asked and how the primary outcome was defined, but does not support a conclusion about whether polymorphism status was associated with PFS or about the size or importance of any relationship.

13. Why This Trial Matters Statistically

This trial is statistically notable because it frames its primary question as an association between genetic polymorphisms and a time-to-event outcome during treatment. That question differs from a conventional treatment-versus-control comparison. Recognizing the distinction helps keep interpretation aligned with the design: a single-group association can be described, but it cannot by itself separate treatment effects from other explanations for differences among participants.

The endpoint definition also matters. PFS combines progression, assessed using RECIST v1.0 criteria, and death from any cause, measured from the first treatment dose. This makes clear which events count and when timing begins. At the same time, a time-to-event estimate depends on follow-up and censoring, details that are not reported in the registry record. An endpoint label alone is not enough to evaluate an estimate.

The record lists many outcomes but no analyses. This illustrates why a registry's outcome inventory and its statistical results are distinct: outcome names do not disclose which comparisons were performed, how uncertainty was quantified, or how multiple questions were handled. Transparent reporting of analysis populations, estimates, and uncertainty is important for evaluating both primary and secondary findings.

Finally, the posted safety counts and serious-event terms can be described, but without a comparison group they do not quantify relative safety. The registry record's structure therefore allows some useful design and endpoint interpretation while leaving central inferential questions unresolved. That distinction—between a clearly stated research question and a reported, interpretable result—is important for clinical research readers.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpretation is that the registry record does not report a numerical result for the primary PFS endpoint. It gives no median, full range, hazard ratio, confidence interval, p-value, or event count for the polymorphism question. Consequently, neither the association's direction nor its precision can be evaluated.

The single-group design has no like-for-like control comparison. Any relationship between polymorphism status and PFS would be observed among participants receiving the combination and could be influenced by other differences among participants. The registry does not report subgroup definitions, covariate adjustment, or an analysis model that would clarify how these issues were addressed.

Enrollment is recorded as 42, but the primary analysis population is not reported. The safety entries list 40 participants at risk, and the record does not explain the relationship between these counts. The number with available polymorphism data, the number included in PFS analyses, follow-up completeness, censoring, and missing-data handling are not reported in the registry record.

The record lists 38 outcome measures and no analyses. It does not identify which outcomes were analyzed, specify an approach to multiplicity, or describe whether analyses were prespecified. Treatment dose and schedule and the trial's sample-size justification are also not reported in the registry record. The planning assumptions stated for sample-size illustrations do not replace a documented rationale for this single-group trial.

These limitations constrain interpretation of the posted information; they do not establish that particular analyses were absent from other materials. The registry record itself does not contain the details required to assess those analyses.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Cetuximab and Lenalidomide in Head and Neck — NCT01133665.
• Registry record last updated 2014-11-24; status last verified 2014-11.
• Results first posted 2014-11-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes NCT01133665, titled Cetuximab and Lenalidomide in Head and Neck, as a completed phase II study sponsored by the University of Chicago. It lists a single-group design, no masking, and enrollment of 42. The study start is recorded as 2010-02 and primary completion as 2011-08.

The intervention is cetuximab and lenalidomide. The primary question concerns the relationship between specific FcRIIIa polymorphisms and progression-free survival in recurrent or metastatic squamous cell carcinoma of the head and neck. PFS is defined from the first treatment dose to progression or death from any cause, with progression based on RECIST v1.0 criteria. The record lists a 24 months timeframe.

The record includes 38 outcome measures and no analyses. It does not report a numerical primary-outcome result or the statistical methods used to assess the polymorphism association. Safety entries list 40 participants at risk in each of two event categories, along with selected serious adverse event terms. These details describe what the registry records, but do not provide a controlled treatment comparison or a numerical PFS finding.